Saamya Biotech (India) IPO
Saamya Biotech (India) IPO — date, price band, lot size & details 2007
Saamya Biotech (India) listed on 19 Oct 2007 at ₹17.5, 75% above the ₹10 issue price.
Saamya Biotech (India) is a Hyderabad based company, set up as a 100% export oriented unit, that planned to make the active pharma ingredients daunomycin and hyaluronic acid. It had no income yet at the time of the IPO.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 12 November.
- Open 25 Sep 2007
- Close 28 Sep 2007
- Allotment 16 Oct 2007
- Refund/credit TBA
- Listing 19 Oct 2007
Issue summary
The terms of the offer, as filed.
| IPO Dates | 25 to 28 Sep, 2007 |
|---|---|
| Price Band | TBA |
| Face Value | ₹10 |
| Lot Size | 500 Shares |
| Issue Size | ₹15.01 Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE |
| Registrar | Aarthi Consultants Pvt.Ltd. |
| Min Investment | ₹ 5,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 500 shares at the ₹10 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 500 | ₹5,000 |
| Retail (max) | 40 | 20,000 | ₹2,00,000 |
| S-HNI (min) | 41 | 20,500 | ₹2,05,000 |
| S-HNI (max) | 200 | 100,000 | ₹10,00,000 |
| B-HNI (min) | 201 | 100,500 | ₹10,05,000 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Net worth was Rs 8.05 crore on 31 March 2007.
- 02It was set up as a 100% export oriented unit.
- 03Its technology partner was Biofin Laboratories of Italy; total assets were Rs 9.56 crore.
- 04The whole Rs 15.01 crore issue was fresh money for the company.
Risks · 5
- 01It had no income at all in the 4 years to March 2007, as the plant was not yet built.
- 02Its process had been tested only at lab or pilot plant scale and never in large scale production, so 2 untested products carried the whole business.
- 03Net worth was only Rs 0.02 crore on 31 March 2005.
- 04Making APIs needs drug approvals before sales can begin, so income could take years; the issue was priced at Rs 10.
- 05Promoter holding fell from 100% before the issue to 35.01% after it, which is very low.
Three years of numbers
All figures in ₹ crore, as reported in the Saamya Biotech (India) offer document.
| Metric | 31 Mar 2007 | 31 Mar 2006 | 31 Mar 2005 |
|---|---|---|---|
| Assets | 9.56 | 8.37 | 1.02 |
| NET Worth | 8.05 | 8.05 | 0.02 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Where the money goes
₹3.42 Cr of the issue is earmarked to named objects.
About the company
It planned to make only active pharma ingredients, namely daunomycin and hyaluronic acid.
The technology came from Biofin Laboratories of Italy and had been tested only at lab or pilot plant scale, not in large scale production.
The IPO was Rs 15.01 crore and was entirely a fresh issue at a fixed price of Rs 10, which was its face value. The money was for setting up its plant.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
040-27638111/27638111/27638111
The bankers & the filings
Who is running the book, and the documents this page is built from.
Saamya Biotech (India) IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Standard Chartered Securities (India) Ltd
24 issues handledBest listing: Vivimed Labs (+87.1%). Weakest: Abhishek Mills (-14.9%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Saamya Biotech (India)?
The current Grey Market Premium is ₹0.
What is the Saamya Biotech (India) IPO price band?
₹10, on a face value of ₹10.
When is the allotment?
The basis of allotment is 16 October 2007, with listing on 19 October 2007.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Aarthi Consultants Pvt.Ltd..
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
